Non-Animal Navigator™

Animal testing has long been a mainstay of drug development. However, over 90% of drugs that appear safe and effective in animals don’t receive FDA approval in humans. In addition to being poor predictors of human safety and efficacy, animal tests– particularly those on non-human primates–  pose ethical issues.  The FDA’s plan to phase out animal testing highlights the need for non-animal testing methods.  

Certara’s Non-Animal Navigator™ empowers you to future-proof your portfolios, gaining a competitive advantage through faster pre-clinical timelines and lower costs. Combining 25+ years of expertise with cutting-edge AI-enabled biosimulation, we help you address the 3Rs to reduce, refine, or replace animal studies. 

Now is the time to future-proof your portfolio with Certara by your side.

Certara delivers tailored solutions to transform your preclinical strategy. With decades of industry-leading experience, we ensure smarter, faster, and more reliable drug development.

Certara is a trusted partner for biopharmaceutical companies and regulatory agencies, with achievements including:

• 80% of PBPK-modeled drugs approved by the FDA are leveraging our technologies.
• Regulatory strategies informed by extensive experience with FDA, EMA, and global authorities.
• Tailored programs that combine in silico models, real-world data, and New Approach Methodologies (NAMs) to reduce preclinical timelines.

Certara’s Non-Animal Navigator™ combines scientific rigor, innovative models, and regulatory alignment to achieve faster, safer, and more ethical results.